References
- Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217–222.
- Gottwald J, Röcken C. The amyloid proteome: a systematic review and proposal of a protein classification system. Crit Rev Biochem Mol Biol. 2021;56(5):526–542.
- Rezk T, Gilbertson JA, Mangione PP, et al. The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis. J Pathol Clin Res. 2019;5(3):145–153.
- Mollee P, Boros S, Loo D, et al. Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry. Clin Proteomics. 2016;13:30.
- Pepys MB, Dyck RF, de Beer FC, et al. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol. 1979;38(2):284–293.
- Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990;323(8):508–513.
- Namba Y, Tomonaga M, Kawasaki H, et al. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541(1):163–166.
- Gallo G, Wisniewski T, Choi-Miura NH, et al. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol. 1994;145(3):526–530.
- Wisniewski T, Golabek AA, Kida E, et al. Conformational mimicry in Alzheimer’s disease. Role of apolipoproteins in amyloidogenesis. Am J Pathol. 1995;147(2):238–244.
- Sakata N, Hoshii Y, Nakamura T, et al. Colocalization of apolipoprotein AI in various kinds of systemic amyloidosis. J Histochem Cytochem. 2005;53(2):237–242.
- Dahlbäck K, Löfberg H, Dahlbäck B. Immunohistochemical demonstration of vitronectin in association with elastin and amyloid deposits in human kidney. Histochemistry. 1987;87(6):511–515.
- Winter M, Tholey A, Krüger S, et al. MALDI-mass spectrometry imaging identifies vitronectin as a common constituent of amyloid deposits. J Histochem Cytochem. 2015;63(10):772–779.
- McGeer PL, Kawamata T, Walker DG. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 1992;579(2):337–341.
- Greene MJ, Sam F, Soo Hoo PT, et al. Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy. Am J Pathol. 2011;178(1):61–68.
- Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021;20(1):68–80.
- Garai K, Verghese PB, Baban B, et al. The binding of apolipoprotein E to oligomers and fibrils of amyloid-β alters the kinetics of amyloid aggregation. Biochemistry. 2014;53(40):6323–6331.
- Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA. 1995;92(10):4299–4303.
- Richards DB, Cookson LM, Barton SV, et al. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Sci Transl Med. 2018;10:eaan3128.
- Nakamura M, Misumi Y, Nomura T, et al. Extreme adhesion activity of amyloid fibrils induces subcutaneous insulin resistance. Diabetes. 2019;68(3):609–616.
- Paoletti AC, Parmely TJ, Tomomori-Sato C, et al. Quantitative proteomic analysis of distinct mammalian mediator complexes using normalized spectral abundance factors. Proc Natl Acad Sci USA. 2006;103(50):18928–18933.
- Cozzolino F, Landolfi A, Iacobucci I, et al. New label-free methods for protein relative quantification applied to the investigation of an animal model of Huntington disease. PLoS One. 2020;15(9):e0238037.
- Miller PR, Taylor RM, Tran BQ, et al. Extraction and biomolecular analysis of dermal interstitial fluid collected with hollow microneedles. Commun Biol. 2018;1:173.
- Hori Y, Hashimoto T, Nomoto H, et al. Role of apolipoprotein E in β-amyloidogenesis: isoform-specific effects on protofibril to fibril conversion of Aβ in vitro and brain Aβ deposition in vivo. J Biol Chem. 2015;290(24):15163–15174.
- Endo Y, Hasegawa K, Nomura R, et al. Apolipoprotein E and clusterin inhibit the early phase of amyloid-β aggregation in an in vitro model of cerebral amyloid angiopathy. Acta Neuropathol Commun. 2019;7(1):12.